PharmaCyte Biotech, Inc. - 04 Sep 2025 Form 4 Insider Report for Q/C TECHNOLOGIES, INC. (TNFA)

Reporting relationship: 10%+ Owner
Issuer ticker: TNFA
Reported as of: 04 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Nov 2025, 16:32:29 UTC
Prior SEC filing: 30 May 2024
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: PharmaCyte Biotech, Inc. By: /s/ Carlos A. Trujillo, Chief Financial Officer

Key filing fact

PharmaCyte Biotech, Inc. filed Form 4 for Q/C TECHNOLOGIES, INC. (TNFA) on 18 Nov 2025.

Key facts

This page summarizes PharmaCyte Biotech, Inc.'s Form 4 filing for Q/C TECHNOLOGIES, INC. (TNFA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 Nov 2025, 16:32.

Change

Previous filing in this sequence was filed on 30 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001157075 Primary reporting owner

PharmaCyte Biotech, Inc.

Relationship: 10%+ Owner
Address: 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS
Signature: PharmaCyte Biotech, Inc. By: /s/ Carlos A. Trujillo, Chief Financial Officer
Signature date: 18 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QCLS transaction Derivative

Series H Convertible Preferred Stock

Purchase

Transaction value
Shares: +889,865
Change %
Price
Shares after: 889,865
Date: 04 Sep 2025
Ownership: Direct
Underlying class: Common stock, par value $0.001 per share
Underlying amount: 889,865
Exercise price
Footnotes: F1

QCLS transaction Derivative

Warrants

Purchase

Transaction value
Shares: +889,865
Change %
Price
Shares after: 889,865
Date: 14 Nov 2025
Ownership: Direct
Underlying class: Common stock, par value $0.001 per share
Underlying amount: 889,865
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.